Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01703468 · ClinicalTrials.gov registry record · Phase 1
Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions
A Phase 1 study of Seizures, sponsored by Roxane Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT01703468 is a Phase 1 study of Seizures that has completed, run by Roxane Laboratories. The registered enrollment target is 59 participants, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01703468, a Phase 1 study of Seizures, has completed, sponsored by Roxane Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
Conditions Studied
Interventions
- DRUG Oxcarbazepine
Study Locations (1)
Texas
- Worldwide Clinical Trials Drug Development Solutions (formerly CEDRA Clinical Research) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-09 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01703468
The ClinicalTrials.gov registry entry for NCT01703468 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 933-participant average among 39 other Seizures trials with a reported enrollment target (94% lower). The listed sponsor is Roxane Laboratories, which has 93 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Seizures appearing as the primary indexed condition, and to 1 intervention - of which Oxcarbazepine is the first listed.
NCT01703468 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01703468 about?
NCT01703468 is a clinical study titled "Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fed Conditions". The objective of this study was to prove the bioequivalence of Roxane Laboratories' Oxcarbazepine Suspension 600 mg under fed conditions
What is the current status of trial NCT01703468?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-09. Estimated completion is 2009-10.
What conditions does trial NCT01703468 study?
This clinical trial studies the following conditions: Seizures.
What interventions are being tested in trial NCT01703468?
The interventions under investigation include: Oxcarbazepine (DRUG).
Who is sponsoring clinical trial NCT01703468?
This trial is sponsored by Roxane Laboratories, which has 93 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01703468 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seizures
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
BHV-7000 Responsive Neurostimulation System (RNS) Study
ACTIVE NOT RECRUITING · Phase 1
-
Phase I Trail for Intramuscular Administration of Midazolam Using An Autoinjector
COMPLETED · Phase 1
-
Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders
COMPLETED · Phase 1
-
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
COMPLETED · Phase 1
-
Glioblastoma Remote Monitoring and Care - Research Protocol
RECRUITING · NA
-
PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.